Eiger BioPharmaceuticals Inc (EIGR.OQ)
EIGR.OQ on NASDAQ Stock Exchange Global Market
9.95USD
23 Apr 2018
9.95USD
23 Apr 2018
Change (% chg)
$-0.50 (-4.78%)
$-0.50 (-4.78%)
Prev Close
$10.45
$10.45
Open
$10.40
$10.40
Day's High
$10.40
$10.40
Day's Low
$9.50
$9.50
Volume
19,323
19,323
Avg. Vol
35,076
35,076
52-wk High
$16.15
$16.15
52-wk Low
$6.15
$6.15
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.00 | -1.110 |
| Sep '17 | 0.00 | -1.095 | |
| Jun '17 | 0.00 | -1.332 | |
| Mar '17 | 0.00 | -1.344 | |
| FY 2016 | Dec '16 | 0.00 | -1.525 |
| Sep '16 | 0.00 | -1.492 | |
| Jun '16 | 0.00 | -1.867 | |
| Mar '16 | 0.00 | -10.418 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 6 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-19 | 6 | 2.08 | 12.47 | 0.00 | 12.47 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 6 | -1.01 | -0.61 | -1.19 | -1.64 |
| Quarter Ending Sep-18 | 6 | -1.00 | -0.53 | -1.26 | -1.60 |
| Year Ending Dec-18 | 6 | -4.24 | -2.32 | -5.31 | -5.06 |
| Year Ending Dec-19 | 6 | -3.80 | -2.42 | -5.10 | -4.94 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 188.22 | 33.60 | |
| P/E High - Last 5 Yrs. | -- | 284.72 | 45.95 | |
| P/E Low - Last 5 Yrs. | -- | 95.76 | 24.93 | |
| Beta | 1.58 | 0.75 | 0.80 | |
| Price to Sales (TTM) | -- | 136.15 | 7.07 | |
| Price to Book (MRQ) | 4.88 | 19.54 | 5.13 | |
| Price to Tangible Book (MRQ) | 4.88 | 24.07 | 6.73 | |
| Price to Cash Flow (TTM) | -- | 122.99 | 25.52 | |
| % Owned Institutions | 77.11 | 11.18 | 2.22 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.28 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.75 | |
| Dividend 5 Year Growth Rate | -- | 1.94 | 3.93 | |
| Payout Ratio(TTM) | -- | 9.18 | 20.35 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 103.73 | 9.02 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 79.72 | 10.83 | |
| Sales - 5 Yr. Growth Rate | -- | 33.87 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 27.18 | -66.87 | 22.25 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 68.10 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 47.46 | 10.26 | |
| Capital Spending - 5 Yr. Growth Rate | -1.73 | 45.48 | 10.37 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.63 | 2.53 |
| Current Ratio (MRQ) | 5.85 | 5.97 | 3.62 |
| LT Debt to Equity (MRQ) | 58.13 | 23.32 | 11.31 |
| Total Debt to Equity (MRQ) | 67.01 | 25.75 | 13.97 |
| Interest Coverage (TTM) | -66.84 | -186.61 | 30.11 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 36.56 | 54.01 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.38 | 52.12 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -152.18 | 15.89 | |
| Operating Margin (TTM) | -- | -563.03 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | -- | -164.18 | 11.25 | |
| Pre-Tax Margin (TTM) | -- | -535.84 | 4.97 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -171.12 | 11.56 | |
| Net Profit Margin (TTM) | -- | -524.81 | 1.58 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -171.01 | 7.89 | |
| Effective Tax Rate (TTM) | -- | -0.44 | 31.30 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.14 | 24.27 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 23,887,722 | 816,988,634 | |
| Net Income/Employee (TTM) | -2,653,000 | 956,935 | 96,050,323 | |
| Receivable Turnover (TTM) | -- | 6.24 | 5.56 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.45 | |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.89 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -81.93 | -0.77 | 10.54 | |
| Return on Assets - 5 Yr. Avg. | -57.63 | 0.70 | 11.56 | |
| Return on Investment (TTM) | -93.23 | -0.74 | 13.19 | |
| Return on Investment - 5 Yr. Avg. | -68.31 | 4.20 | 14.97 | |
| Return on Equity (TTM) | -134.24 | -2.80 | 15.00 | |
| Return on Equity - 5 Yr. Avg. | -411.73 | -0.05 | 16.25 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | 37.96 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eiger BioPharmaceuticals Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018
- BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11
- UPDATE 2-Eiger to abandon blood pressure drug after trial failure
- BUZZ-Eiger BioPharma: Abandons blood pressure drug after trial failure
- Eiger BioPharma abandons blood pressure drug after failed study
Institutional Holders
| % Shares Owned: | 77.11% |
| # of Holders: | 66 |
| Total Shares Held: | 8,117,131 |
| 3 Mo. Net Change: | 34,793 |
| # New Positions: | 4 |
| # Closed Positions: | 1 |
| # Increased Positions: | 4 |
| # Reduced Positions: | 1 |
| # Net Buyers: | 3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.